Triple Therapy in T1DM

NCT03899402 on ClinicalTrials.gov · last registry update 2026-05-29

Closed to new participants; the 78 already enrolled are still being followed. The sponsor logged completion for 31 January 2026. Primary outcome, as filed: Change in HbA1c following dapagliflozin. semaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ACTIVE_NOT_RECRUITING
Phase: P2/P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: State University of New York at Buffalo
Sponsor type: Other
Enrollment: 78
Started: 2019-05-01
Primary completion: 2026-01-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c following dapagliflozin

Conditions studied

Type 1 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.